Compounds studied for their effect on endogenous growth hormone secretion — growth hormone releasing hormone analogs and growth hormone secretagogues. Effects on hormone levels are far better characterised than effects on clinical outcomes.
This is a field of scientific investigation, not a category of treatment. A compound listed here has been studied in this context; that is not a claim that it treats any condition. See how we grade the evidence.
Also known as CJC-1295 with DAC, DAC:GRF, Drug Affinity Complex GHRH analog
Growth Hormone & Endocrine Research
A long-acting analog of growth hormone-releasing hormone. Early human trials established that it raises GH and IGF-1 for days after a single dose — but hormone levels are a surrogate, not a clinical outcome.
Growth Hormone & Endocrine Research • Gastrointestinal Research
A selective growth hormone secretagogue that reached Phase 2 human trials for postoperative ileus — where it missed its primary endpoint. One of the few compounds in this space with a published, well-conducted negative trial.
Growth Hormone & Endocrine Research • Metabolic Research
The only GHRH-class analog with FDA approval. Approved narrowly — for reducing excess visceral abdominal fat in adults with HIV and lipodystrophy — and explicitly not indicated for weight loss.
Half-life is the single number that decides whether a peptide can be a once-weekly medicine or nothing at all. How it is measured, how it is engineered, and how it is misused in marketing.
Investigational, approved, discontinued and unstudied are four different states, and compounds in all four are sold side by side. How to tell them apart.
Nine questions that separate a study which tells you something from one that only looks like it does — written for readers without a research background.